Veteran healthcare executive and investor with operational and board experience across medical device and services companies. Kent D. Aloia has led strategic growth, M&A and commercialization initiatives and often partners with PE firms to scale specialty healthcare businesses. Known for combining surgical practice insight with corporate governance, he has served as CEO and board director roles and advised growth-stage management teams on product strategy and market development. Relevant to investors seeking experienced operating partners in healthcare roll-ups, digital health and device commercialization.
Veteran healthcare executive and investor with operational and board experience across medical device and services companies. Kent D. Aloia has led strategic growth, M&A and commercialization initiatives and often partners with PE firms to scale specialty healthcare businesses. Known for combining surgical practice insight with corporate governance, he has served as CEO and board director roles and advised growth-stage management teams on product strategy and market development. Relevant to investors seeking experienced operating partners in healthcare roll-ups, digital health and device commercialization.
Seasoned healthcare operating partner who prioritizes equity investments that leverage deep medical-device and specialty services expertise to accelerate commercialization and roll-up strategies. Prefers control or structured minority stakes where active governance, clinical insights and go-to-market operational resources can derisk regulatory and reimbursement pathways. Focuses on multi-year value creation through M&A-driven scale, product-market fit, and commercialization execution, applying disciplined capital allocation, milestone-based funding and outcome-oriented KPIs to balance growth and clinical/risk governance.
Seasoned healthcare operating partner who prioritizes equity investments that leverage deep medical-device and specialty services expertise to accelerate commercialization and roll-up strategies. Prefers control or structured minority stakes where active governance, clinical insights and go-to-market operational resources can derisk regulatory and reimbursement pathways. Focuses on multi-year value creation through M&A-driven scale, product-market fit, and commercialization execution, applying disciplined capital allocation, milestone-based funding and outcome-oriented KPIs to balance growth and clinical/risk governance.
| Trades 587 | Longs Won 450/587 76% | Profit Factor 41.68 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $587,174.91 |
| Average Win $111,222.12 | Best Trade (Jul 10) $12.33M | Sharpe Ratio -14.38 |
| Average Loss -$8,764.9 | Worst Trade (Dec 30) -$139,058 | Z-Score 17.03 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 2w 2d | Expectancy $83,218.34 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 23,256 | 20,930 | 18,605 | 16,279 | 13,953 | 11,628 | 9,302 | 6,977 | 4,651 | 2,326 |